Scipio bioscience

Stuart is a world-renowned biophysicist. A foreign associate of the French Academy of Science, his academic curriculum includes professorships at Cornell University (NY, USA), University of Geneva (Switzerland), ENS (Paris, France) and the Collège de France. Stuart also has start-up experience as co-founder of a publicly listed biotech company.

A seasoned veteran of start-ups and larger companies in life sciences, founder of two successful businesses and director of large R&D teams at Bio-Rad and other organizations, Pierre brings a broad experience in both science and business management. After 2 years as VP Chief Manufacturing Officer, he took on the mantle of CEO to lead Scipio bioscience in its evolution towards new markets and the expansion of its range of novel single-cell applications.

As Scipio’s Chief Business Officer Marie-Claude took a role aligned with her passion to bring world-changing innovations to market, enabling scientific discoveries and ultimately improving the life of millions of patients! Marie-Claude comes with a vast experience in different environments from start-ups to leading large teams in public corporations like QIAGEN around the globe. She has earned the reputation of a dynamic, collaborative, high-achieving executive. As a senior venture capital advisor, she also assesses hundreds of startup business plans providing her with an all-encompassing view of a start-up journey.

Jun has 10+ years of experience in biotech R&D and is an expert in structural and functional analysis of DNA molecules for genetic testing and biomedical research. With a background in general engineering and industrial chemistry, he received his PhD on the subject of micromanipulation of biological molecules in an electrostatics laboratory of the Toyohashi University of Technology (Japan).

A Telecom Engineer graduate, Vivien has 12 years of experience in the IT industry. He started as a Java Developer before advancing his career as an IT Architect. He has extensive experience in different contexts, such as Security, Banking, and Energy. Vivien joined Scipio in July 2021 to set up DevOps practices and lead the way into Cloud technology for Cytonaut. With his project management experience, he is now leading the entire bioinformatic team to take Cytonaut to new heights.

A seasoned business-oriented finance professional experienced in growing innovative MedTech companies and executive roles as CFO on a global scale within both in International multi-site organizations and in start-ups helping them scale from seed to series B. She thrives in fast paced environments and excel in both details and high-level strategy. She provides strong support to the CEO in investor relations, structuring financial processes and cash management.

Philippe, a partner at Seventure Partners, is in charge of life siences investments for the Quadrivium I fund. He started his career as a Project Manager and Director of Business Development Europe in the Rhodia group and later founded a market and business intelligence company, CBDMT – Market & Business Intelligence, which he managed for 10 years prior to joining Seventure.

Jean-Pascal Viola is the Senior Vice-President, Head of the Molecular Diagnostics Business Area at QIAGEN, in addition to his role as leader of corporate business development and intellectual property and litigation. He joined Qiagen in 2005 and has held various roles in Singapore, the US, and Germany. He played a leading role in the acquisitions of Cellestis, Stat-Dx, NeuMoDx, and the assets of Formulatrix related to digital PCR.

Nathalie is Associate Vice-President, head of the Program Management Office of the Diagnostics and Genomics Group at Agilent Technologies. After 5 years as a researcher in microfluidics, including a PhD on single cell transcriptome analysis and a patent on monodisperse emulsions, Nathalie joined Agilent Technologies. With 15 years of WW commercial and operational experience, in roles ranging from field marketing, sales, operations and business development, Nathalie brings an outstanding track record of building teams and driving transformation in highly complex, cross-cultural environments.

Oliver Hardick, EngD, is Entrepreneur in Residence (EIR) at M Ventures, and is a successful Tech Entrepreneur with core expertise in the bioprocessing field. Completing his Engineering Doctorate at UCL 2012, he moved into the entrepreneurial world founding Puridify, a biotech tools company, in 2013 based on his academic research. He led as CEO through VC funding to a strong exit by GE Healthcare in 2017. Having spent 5 years leading an SME followed by 5 years in a large corporate he understands the needs of both and can provide key insights to spin-outs & start-ups from inception to exit. OIiver is based in London and Amsterdam.

Frank is Senior Investment Manager at High-Tech Gründerfonds. He brings significant experience in biotechnology, as a scientist and founder of OncoMab GmbH, a spin-off of the University of Würzburg's Institute of Pathology. This expert in tumour-reactive antibodies focuses on the development of biologicals from the manufacturing phase to the clinical-trial stage.

Louis Geslin joined Financière Arbevel in 2016 as an equity analyst in the healthcare sector. Since 2018, he has co-managed the unlisted Arbevel Life Sciences Crossover I fund. Louis began his career in the hospital sector (Hôpital Timone, Institut Paoli-Calmettes) and then in venture capital funds (Seventure Partners, Advent Life Sciences, Bpifrance). Louis is a Board member at NG Biotech, Imactis, TransCure BioServices and Germitec and a Board observer at UroMems. Louis holds a pharmacy degree and is a graduate of the ESSEC Grande Ecole program.

Christian joined M Ventures in August 2019 and is a Principal in the Biotechnology team. Before joining M Ventures he worked at Merck as Healthcare and Life Science focused inhouse consultant. Prior, he worked as an ext. consultant focused on Biopharma/tech and Tech for more than a decade. Christian holds an MBA from Mannheim Business School, Germany and a Diploma in Computer Science and Business Administration (Business Informatics) from Cooperative State University Karlsruhe, Germany. Christian is based in Darmstadt.

EIC Fund, venture investment arm of the European Investment Council. Maxime specializes in VC and growth equity in deep tech and impact companies.